Gut Bacteria Linked to Parkinson’s Disease: Could Better Oral Hygiene Offer Protection?
Table of Contents
A growing body of research suggests a surprising connection between oral health and neurological disorders. New findings indicate that bacteria originating in the mouth can migrate to the gut and potentially influence brain function, offering a novel perspective on the development of Parkinson’s disease.
Researchers in South Korea have uncovered compelling evidence of a biological pathway linking oral bacteria to the onset of Parkinson’s. The study, published in Nature Communications, identifies a specific bacterium and its metabolic byproducts as potential contributors to the disease’s progression. This discovery could pave the way for innovative preventative and therapeutic strategies.
The Mouth-Gut-Brain Connection
For years, scientists have observed differences in the gut bacteria of individuals with Parkinson’s compared to healthy controls. However, pinpointing the specific microbes involved and understanding how they impact the disease remained elusive. This new research sheds light on this complex relationship.
The collaborative team, led by Professor Ara Koh and doctoral candidate Hyunji Park from POSTECH, along with researchers from Sungkyunkwan University School of Medicine and Seoul National University College of Medicine, focused on identifying the mechanisms at play. Their investigation revealed a surprising suspect: Streptococcus mutans, a bacterium commonly associated with dental cavities.
A Cavity-Causing Culprit
The researchers discovered elevated levels of S. mutans in the gut microbiomes of people diagnosed with Parkinson’s. This bacterium produces an enzyme called urocanate reductase (UrdA), which in turn generates a metabolic byproduct known as imidazole propionate (ImP). Both UrdA and ImP were found in increased concentrations in the gut and bloodstream of patients.
Evidence suggests that ImP isn’t confined to the periphery; it can cross biological barriers and reach the brain. Once there, it appears to contribute to the degeneration of dopamine-producing neurons, a hallmark of Parkinson’s disease.
Evidence from Mouse Models
To validate these findings, the team conducted experiments using mice. Introducing S. mutans directly into the animals’ guts, or genetically modifying E. coli to produce UrdA, led to a rise in ImP levels in both blood and brain tissue. The mice subsequently exhibited key characteristics associated with Parkinson’s, including:
- Damage to dopaminergic neurons
- Increased brain inflammation
- Movement difficulties
- Accumulation of alpha-synuclein, a protein strongly linked to disease progression.
Targeting mTORC1 for Potential Treatment
Further investigation revealed that the harmful effects of ImP were dependent on the activation of a signaling protein complex called mTORC1. When mice were treated with a drug to inhibit mTORC1, researchers observed a significant reduction in brain inflammation, neuron loss, alpha-synuclein buildup, and motor impairments.
“Our study provides a mechanistic understanding of how oral microbes in the gut can influence the brain and contribute to the development of Parkinson’s disease,” said Professor Ara Koh. “It highlights the potential of targeting the gut microbiota as a therapeutic strategy, offering a new direction for Parkinson’s treatment.”
These results suggest that modulating the oral-gut microbiome and the compounds it produces could represent a promising avenue for treating – and potentially preventing – Parkinson’s disease. The research was supported by the Samsung Research Funding & Incubation Center of Samsung Electronics, the Mid-Career Researcher Program of the Ministry of Science and ICT, the Microbiome Core Research Support Center, and the Biomedical Technology Development Program.
